-transparent.png){kind=logo}
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. 2004
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy.
A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
Related Publications
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
August 2004,
British journal of cancer,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
August 2008,
British journal of cancer,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
October 2000,
Oncology (Williston Park, N.Y.),
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
October 2000,
Oncology (Williston Park, N.Y.),
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
October 2010,
Anticancer research,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
January 2006,
The oncologist,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
May 2007,
Clinical colorectal cancer,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
August 2007,
British journal of cancer,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
June 2010,
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,
R Petrioli, and
M Sabatino, and
A I Fiaschi, and
S Marsili, and
D Pozzessere, and
S Messinese, and
P Correale, and
S Civitelli, and
G Tanzini, and
F Tani, and
A De Martino, and
G Marzocca, and
M Lorenzi, and
G Giorgi, and
G Francini
August 2002,
American journal of clinical oncology,
